Obovatol improves cognitive functions in animal models for Alzheimer's disease

Journal of Neurochemistry

Volumn 120, Issue 6, 2012, Pages 1048-1059

  Choi, Dong Young ^a   Lee, Jae Woong ^a   Peng, Jin ^a   Lee, Young Jung ^a   Han, Jin Yi ^a   Lee, Yeon Hee ^a   Choi, Im Seop ^a   Han, Sang Bae ^a   Jung, Jae Kyung ^a   Lee, Woong Soo ^b   Lee, Seung Ho ^c   Kwon, Byoung Mog ^d   Oh, Ki Wan ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Chungju National University   (South Korea)

^c KT and G Central Research Institute   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Alzheimer's disease; Amyloid beta; Neuroinflammation; NF kappaB; Obovatol; Tg2576

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; GAMMA SECRETASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNOLIA EXTRACT; OBOVATOL; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG STRUCTURE; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; INHIBITION KINETICS; MACROGLIA; MAGNOLIA OBOVATA; MAGNOLIACEAE; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TASK PERFORMANCE; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BIPHENYL COMPOUNDS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PHENYL ETHERS;

ANIMALIA; MAGNOLIA OBOVATA; MUS; MUS MUSCULUS;

EID: 84862776547     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07642.x     Document Type: Article

References (67)

1. Benzing W. C., Wujek J. R., Ward E. K., Shaffer D., Ashe K. H., Younkin S. G. and Brunden K. R. (1999) Evidence for glialmediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 20, 581-589. (Pubitemid 30064403)
2. Bourne K. Z., Ferrari D. C., Lange-Dohna C., Rossner S., Wood T. G. and Perez-Polo J. R. (2007) Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 85, 1194-1204. (Pubitemid 46724363)
3. Braida D., Sacerdote P., Panerai A. E., Bianchi M., Aloisi A. M., Iosue S. and Sala M. (2004) Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav. Brain Res. 153, 423-429. (Pubitemid 38953117)
4. Cai X. D., Golde T. E. and Younkin S. G. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514-516. (Pubitemid 23058708)
5. Caughey B. and Lansbury P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298. (Pubitemid 37064935)
6. Chen C. H., Zhou W., Liu S., Deng Y., Cai F., Tone M., Tone Y., Tong Y. and Song W. (2011) Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int. J. Neuropsychopharmacol. 15, 77-90.
7. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. and Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360, 672-674. (Pubitemid 23007680)
8. Cole S. L. and Vassar R. (2008) The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 283, 29621-29625.
9. Craft J. M., Watterson D. M. and Van Eldik L. J. (2006) Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 53, 484-490.
10. Dong Y. F., Kataoka K., Tokutomi Y. et al. (2011) Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 25, 2911-2920.
11. Drouet B., Pincon-Raymond M., Chambaz J. and Pillot T. (2000) Molecular basis of Alzheimer's disease. Cell. Mol. Life Sci. 57, 705-715. (Pubitemid 30392029)
12. Ehrnhoefer D. E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A. and Wanker E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566. (Pubitemid 351799141)
13. Emre M., Geula C., Ransil B. J. and Mesulam M. M. (1992) The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol. Aging 13, 553-559.
14. Fujita S. and Taira J. (1994) Biphenyl compounds are hydroxyl radical scavengers: their effective inhibition for UV-induced mutation in Salmonella typhimurium TA102. Free Radic. Biol. Med. 17, 273-277. (Pubitemid 24269680)
15. Fujiwara H., Tabuchi M., Yamaguchi T. et al. (2009) A traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose have potent antiaggregation effects on Alzheimer's amyloid beta proteins in vitro and in vivo. J. Neurochem. 109, 1648-1657.
16. Fukumoto H., Takahashi H., Tarui N. et al. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J. Neurosci. 30, 11157-11166.
17. Glabe C. G. (2008) Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643.
18. Glass C. K., Saijo K., Winner B., Marchetto M. C. and Gage F. H. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
19. Han H., Jung J. K., Han S. B., Nam S. Y., Oh K. W. and Hong J. T. (2011) Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx. J. Med. Food 14, 724-731.
20. Heneka M. T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453. (Pubitemid 40826196)
21. Holsinger R. M., McLean C. A., Beyreuther K., Masters C. L. and Evin G. (2002) Increased expression of the amyloid precursor betasecretase in Alzheimer's disease. Ann. Neurol. 51, 783-786. (Pubitemid 34568861)
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
23. Hwang D. Y., Chae K. R., Kang T. S. et al. (2002) Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J. 16, 805-813. (Pubitemid 34615129)
24. Kim J. C., Lee S. Y., Kim S. Y. et al. (2008) HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha. FEBS Lett. 582, 2371-2376.
25. Kim T. I., Lee Y. K., Park S. G. et al. (2009) l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic. Biol. Med. 47, 1601-1610.
26. Kotilinek L. A., Westerman M. A., Wang Q. et al. (2008) Cyclooxygenase- 2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651-664. (Pubitemid 351294724)
27. Kukar T., Prescott S., Eriksen J. L., Holloway V., Murphy M. P., Koo E. H., Golde T. E. and Nicolle M. M. (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8, 54.
28. Kuribara H., Stavinoha W. B. and Maruyama Y. (1998) Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plusmaze test in mice. J. Pharm. Pharmacol. 50, 819-826. (Pubitemid 28379279)
29. Kwon B. M., Ro S. H., Kim M. K., Nam J. Y., Jung H. J., Lee I. R., Kim Y. K. and Bok S. H. (1997) Polyacetylene analogs, isolated from hairy roots of Panax ginseng, inhibit Acyl-CoA : cholesterol acyltransferase. Planta Med. 63, 552-553.
30. Lee J. W., Lee Y. K., Ban J. O., Ha T. Y., Yun Y. P., Han S. B., Oh K. W. and Hong J. T. (2009a) Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NFkappaB pathways in mice. J. Nutr. 139, 1987-1993.
31. Lee S. Y., Cho J. S., Yuk D. Y. et al. (2009b) Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J. Pharmacol. Sci. 111, 124-136.
32. Lee Y. K., Yuk D. Y., Kim T. I., Kim Y. H., Kim K. T., Kim K. H., Lee B. J., Nam S. Y. and Hong J. T. (2009c) Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J. Nat. Med. 63, 274-282.
33. Lee J. W., Lee Y. K., Lee B. J., Nam S. Y., Lee S. I., Kim Y. H., Kim K. H., Oh K. W. and Hong J. T. (2010) Inhibitory effect of ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol. Biochem. Behav. 95, 31-40.
34. Lee Y. J., Choi D. Y., Choi I. S., Han J. Y., Jeong H. S., Han S. B., Oh K. W. and Hong J. T. (2011a) Inhibitory effect of a tyrosinefructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2- butenal on amyloid-beta generation and inflammatory reactions via inhibition of NF-kappaB and STAT3 activation in cultured astrocytes and microglial BV-2 cells. J. Neuroinflammation 8, 132.
35. Lee Y. J., Lee Y. M., Lee C. K., Jung J. K., Han S. B. and Hong J. T. (2011b) Therapeutic applications of compounds in the Magnolia family. Pharmacol. Ther. 130, 157-176.
36. Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
37. Li N., Song Y., Zhang W., Wang W., Chen J., Wong A. W. and Roberts A. (2007) Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul. Toxicol. Pharmacol. 49, 154-159. (Pubitemid 350087392)
38. Lim G. P., Yang F., Chu T. et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714. (Pubitemid 30636898)
39. Lin Y. R., Chen H. H., Ko C. H. and Chan M. H. (2006) Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur. J. Pharmacol. 537, 64-69.
40. Liu Z., Zhang X., Cui W., Li N., Chen J., Wong A. W. and Roberts A. (2007) Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats. Regul. Toxicol. Pharmacol. 49, 160-171. (Pubitemid 350087393)
41. Ma H., Jo Y. J., Ma Y., Hong J. T., Kwon B. M. and Oh K. W. (2009) Obovatol isolated from Magnolia obovata enhances pentobarbitalinduced sleeping time: possible involvement of GABAA receptors/ chloride channel activation. Phytomedicine 16, 308-313.
42. Maruyama Y., Kuribara H., Morita M., Yuzurihara M. and Weintraub S. T. (1998) Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine. J. Nat. Prod. 61, 135-138. (Pubitemid 28086994)
43. Medeiros R., Figueiredo C. P., Pandolfo P., Duarte F. S., Prediger R. D., Passos G. F. and Calixto J. B. (2010) The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav. Brain Res. 209, 165-173.
44. Munroe M. E., Arbiser J. L. and Bishop G. A. (2007) Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J. Immunol. 179, 753-763.
45. Ock J.,HanH. S.,HongS.H., LeeS.Y., HanY.M., KwonB.M. andSukK. (2010) Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br. J. Pharmacol. 159, 1646-1662.
46. Ralay Ranaivo H., Craft J. M., Hu W., Guo L., Wing L. K., Van Eldik L. J. and Watterson D. M. (2006) Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J. Neurosci. 26, 662-670. (Pubitemid 43237131)
47. Riviere C., Richard T., Vitrac X., Merillon J. M., Valls J. and Monti J. P. (2008) New polyphenols active on beta-amyloid aggregation. Bioorg. Med. Chem. Lett. 18, 828-831.
48. Rovelet-Lecrux A., Hannequin D., Raux G. et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24-26. (Pubitemid 43011878)
49. Salminen A., Ojala J., Kauppinen A., Kaarniranta K. and Suuronen T. (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181-194.
50. Sambamurti K., Kinsey R., Maloney B., Ge Y. W. and Lahiri D. K. (2004) Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 18, 1034-1036. (Pubitemid 39561516)
51. Sastre M., Dewachter I., Rossner S. et al. (2006) Nonsteroidal antiinflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 103, 443-448. (Pubitemid 43122420)
52. Sastre M., Walter J. and Gentleman S. M. (2008) Interactions between APP secretases and inflammatory mediators. J. Neuroinflammation 5, 25.
53. Seo J. J., Lee S. H., Lee Y. S., Kwon B. M., Ma Y., Hwang B. Y., Hong J. T. and Oh K. W. (2007) Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1363-1369. (Pubitemid 47302547)
54. Shen C. C., Ni C. L., Shen Y. C., Huang Y. L., Kuo C. H., Wu T. S. and Chen C. C. (2009) Phenolic constituents from the stem bark of Magnolia officinalis. J. Nat. Prod. 72, 168-171.
55. Stewart W. F., Kawas C., Corrada M. and Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632. (Pubitemid 27120096)
56. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos Jr L., Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340.
57. Szekely C. A., Thorne J. E., Zandi P. P., Ek M., Messias E., Breitner J. C. and Goodman S. N. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159-169. (Pubitemid 38980441)
58. Tancredi V., D'Arcangelo G., Grassi F., Tarroni P., Palmieri G., SantoniA. and Eusebi F. (1992) Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 146, 176-178.
59. Trepanier C. H. and Milgram N. W. (2010) Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J. Alzheimers Dis. 21, 1089-1099.
60. Tsai T. H., Chou C. J. and Chen C. F. (1996) Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J. Pharm. Pharmacol. 48, 57-59. (Pubitemid 26128686)
61. Vassar R. and Citron M. (2000) Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron 27, 419-422.
62. Vorhees C. V. and Williams M. T. (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848-858.
63. Walker D. and Lue L. F. (2007) Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr. Neuropharmacol. 5, 232-243. (Pubitemid 350268184)
64. Wyss-Coray T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015.
65. Yan J. J., Cho J. Y., Kim H. S., Kim K. L., Jung J. S., Huh S. O., Suh H. W., Kim Y. H. and Song D. K. (2001) Protection against betaamyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol. 133, 89-96.
66. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M. and Landreth G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509. (Pubitemid 37034066)
67. Yankner B. A. (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.